Antoine Yver - Sep 30, 2022 Form 4/A - Amendment Insider Report for Centessa Pharmaceuticals plc (CNTA)

Signature
/s/ Gregory Weinhoff, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Sep 30, 2022
Transactions value $
-$37,108
Form type
4/A - Amendment
Date filed
11/23/2022, 04:01 PM
Date Of Original Report
Oct 4, 2022
Previous filing
Sep 2, 2022
Next filing
Nov 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Sale -$37.1K -9.5K -1.2% $3.91 780K Oct 3, 2022 Direct F1, F3, F4, F5, F6
holding CNTA Ordinary Shares 790K Sep 30, 2022 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The transaction on September 30, 2022 previously reported on the Form 4 filed on October 4, 2022 was canceled in its entirety before settlement by the broker without instruction from the Issuer or Reporting Person.
F3 The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted shares. These sales were automatic and intended to qualify under Rule 10b5-1.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.8800 to $3.9250, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F5 The Form 4 filed on October 4, 2022 reported an aggregate of 12,524 shares sold on October 3, 2022, of which (i) the transaction for the sale of 3,024 shares was canceled in its entirety before settlement by the broker without instruction from the Issuer or Reporting Person and (ii) 9,500 shares were sold as previously reported on the Form 4. No additional sales are being reported herein.
F6 This amendment shall also be deemed to correct the total beneficial ownership reported by the Reporting Person in the subsequently filed Form 4 on November 3, 2022.